


L5 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN
RN 135463-81-9 REGISTRY
ED Entered STN: 09 Aug 1991
CN 1-Pyrrolidineacetamide, 2-oxo-N-(5,6,7,8-tetrahydro-2,3-dimethylfuro[2,3-b]quinolin-4-yl)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Furo[2,3-b]quinoline, 1-pyrrolidineacetamide deriv.
OTHER NAMES:
CN Coluracetam
CN MKC 231
MF C19 H23 N3 O3
SR CA
LC STN Files: ADISINSIGHT, BIOSIS, BIOTECHNO, CA, CAPLUS, CIN, EMBASE, IMSDRUGNEWS, IMSRESEARCH, MEDLINE, PHAR, PROMT, PROUSDDR, SCISEARCH, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

14 REFERENCES IN FILE CA (1907 TO DATE)
14 REFERENCES IN FILE CAPLUS (1907 TO DATE)

FILE 'HOME' ENTERED AT 15:20:55 ON 29 JAN 2007

=> file reg
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 15:21:09 ON 29 JAN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 28 JAN 2007 HIGHEST RN 918629-37-5
DICTIONARY FILE UPDATES: 28 JAN 2007 HIGHEST RN 918629-37-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.


REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>
Uploading C:\Program Files\Stnexp\Queries\schizophrenia.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 fam sam
SAMPLE SEARCH INITIATED 15:21:38 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 0 TO 0
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA FAM SAM L1


=> s l1 fam full
FULL SEARCH INITIATED 15:21:50 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 3 TO ITERATE

100.0% PROCESSED 3 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

L3 1 SEA FAM FUL L1

=> d scan

L3 1 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Pyrrolidineacetamide, 2-oxo-N-(5,6,7,8-tetrahydro-2,3-dimethylfuro[2,3-b]quinolin-4-yl)- (9CI)
MF C19 H23 N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> file caplus
COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
68.15	68.36

FILE 'CAPLUS' ENTERED AT 15:22:17 ON 29 JAN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 29 Jan 2007 VOL 146 ISS 6
FILE LAST UPDATED: 28 Jan 2007 (20070128/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:


<http://www.cas.org/infopolicy.html>

=> s l3
L4 14 L3

=> d ti au abs so py 1-14

L4 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
TI "Lead Hopping". Validation of Topomer Similarity as a Superior Predictor of Similar Biological Activities
AU Cramer, Richard D.; Jilek, Robert J.; Guessregen, Stefan; Clark, Stephanie J.; Wendt, Bernd; Clark, Robert D.
AB Two extensive studies quantifying the ability of topomer shape similarity to forecast a variety of biol. similarities are described. In a prospective trial of "lead hopping", using topomer similarity for virtual screening and queries from the patent literature, biol. assays of 308 selected compds. (representing 0.03% of those available, per assay type) yielded 11 successful "lead hops" in the 13 assays attempted. The hit rate averaged over all assays was 39% ("activity" defined as inhibition $\geq 20\%$ at 10 μM), significantly greater than an unexpectedly high neg. control hit rate of 15%. The average "Tanimoto 2D fingerprint similarity" between query and "lead hop" structures (0.36) was little more than the Tanimoto similarity between random drug-like structures. Topomer shape and Tanimoto 2D fingerprint similarities were also compared retrospectively, in their tendencies to concentrate together potential and actual drugs reported to belong to the same "activity class", for twenty classes. Among the most similar 3% of structures (corresponding to " ≥ 0.85 Tanimoto" for these structures), an average of 62% of the topomer similar selection possessed a near neighbor belonging to the same activity class, roughly a one-third superiority over the "Tanimoto ≥ 0.85 " selection containing 48% actives in avoiding false positives. Conversely, the least similar 75% of structures contained 0.3% actives for topomer similarity vs. 1.0% actives for Tanimoto 2D fingerprint similarity, a 3-fold superiority for topomers in avoiding false negatives.
SO Journal of Medicinal Chemistry (2004), 47(27), 6777-6791
CODEN: JMCMAR; ISSN: 0022-2623
PY 2004

L4 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
TI Fused pyridine derivative used as therapeutic agent for schizophrenia
IN Bessho, Tomoko; Takashina, Ken
GI



AB Disclosed is a drug that is useful for treating schizophrenia and cognitive dysfunction. In particular, disclosed is a therapeutic agent for schizophrenia comprising as an active ingredient a fused pyridine derivative (I), e.g. a 4-acylamino-5,6,7,8-tetrahydrofuro[2,3-b]quinoline derivative, or its optical enantiomorph or acid adduct salt, or a hydrate or solvate thereof, [wherein R1 = C2-6 alkyl, CH2NR2R3 [wherein R2 = H, acetyl; R2 = R3 = C1-6 alkyl, cycloalkyl, CH(R4)CO2R5 (R4, R5 = H, C1-6 alkyl)]; or NR2R3 together represents 2-oxopyrrolidin-1-yl, 1H-imidazol-1-yl, (un)substituted 2,4-dioxoimidazolidin-1-yl; A = (CH2)3, (CH2)4, CH:CHCH:CH, SCH:CH, CH:CH CH:N, CH:CHN:CH, each (un)substituted CH:CHS, CH:CHO, or N:CHO; B = (CH2)3, (un)substituted (CH2)4, or CHCH2CH2, N-(un)substituted CH2NHCH2CH2, etc.]. 2-(2-Oxopyrrolidin-1-yl)-N-(2,3-dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)acetamide at 10 mg/kg in Wistar male rats significantly improved passive avoidance reaction.

SO PCT Int. Appl., 31 pp.

CODEN: PIXXD2

PY 2004
2004
2005
2006
2006

L4 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN

TI Preventives/remedies for cholinergic neuropathy

IN Takashina, Ken; Bessho, Tomoko

AB Preventives/remedies for cholinergic neuropathy which contain as the active ingredient a drug capable of increasing the choline transporter count on the cell membrane surface of cholinergic neurons or a drug capable of acting on intracellular localized changes in choline transporters and thus increasing the choline transporter count on the cell membrane surface. Thus, it becomes possible to provide drugs allowing epoch making administration on the basis of the drug effect mechanism (namely, administration twice or less per day without considering the blood half-time of the drug). Thus, the compliance of a patient with a need for the drug therapy can be improved and the load of a caregiver can be relieved.

SO PCT Int. Appl., 57 pp.

CODEN: PIXXD2

PY 2003
2003
2004
2004

L4 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN

TI Polymorph forms of n-(2,3-dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)-2-(2-oxopyrrolidin-1-yl)acetamide

IN Yamabe, Haruko; Ishige, Takanori

AB The invention relates to novel polymorph crystal forms A and B of N-(2,3-dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)-2-(2-oxopyrrolidin-1-yl)acetamide. The compds. and pharmaceutical compns. thereof are useful for activating a malfunctioned cholinergic neuron that is associated with memory loss disturbances.

SO PCT Int. Appl., 35 pp.

CODEN: PIXXD2

PY 2002
2002
2004
2004
2004
2004
2005

L4 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
 TI 4-Acylaminotetrahydrofuro[2,3-b]quinoline derivatives for prevention and
 treatment of ischemic retinopathy and retinal and optic nerve injury
 IN Togawa, Shunji; Mano, Tomiya; Yano, Shinji
 AB 4-Acylaminotetrahydrofuro[2,3-b]quinoline derivs. and their salts are
 claimed for prevention and treatment of ischemic retinopathy and retinal
 and optic nerve injury. The neuroprotectant effects of
 2-(2-oxopyrrolidin-1-yl)-N-(2,3-dimethyl-5,6,7,8-tetrahydrofuro[2,3-
 b]quinolin-4-yl)acetoamide against retinal injury were tested.
 SO Jpn. Kokai Tokkyo Koho, 7 pp.
 CODEN: JKXXAF
 PY 2001

L4 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
 TI MKC-231, Mitsubishi-Tokyo Pharmaceutical Inc
 AU Chen, Yun
 AB A review with 37 refs. Mitsubishi-Tokyo (formerly Mitsubishi Chemical), in
 collaboration with Takeda, is developing MKC-231, which is an
 acylaminopyridine high-affinity choline uptake facilitator, for the
 potential treatment of Alzheimer's disease (AD) and amnesia. MKC-231 was
 first reported to be in clin. trials in 1993. In Nov. 1999, it was in
 phase II for AD. Administration of MKC-231 resulted in significant
 improvements in a number of models of learning and memory disorders in rats.
 The mechanism of action of MKC-231 appears to be improvement of reduced
 acetylcholinergic nerve activity. Restoration of destruction to the
 basilar region of the forebrain was observed 24 h following administration of
 MKC-231, and acetylcholine content in the cerebral cortex increased.
 MKC-231 promoted the high-affinity uptake of choline in the nerve
 terminals and activated acetylcholinergic nerves by increasing
 acetylcholine synthesis. MKC-231 ameliorated the learning impairment of
 AF64-A-treated rats in the Morris water maze, and repeated administration
 of MKC-231 improved memory deficits in passive avoidance tests and
 reversed the decrease in acetylcholine content in rats with basal
 forebrain lesions produced by bilateral ibotenic acid injections.
 SO Current Opinion in Central & Peripheral Nervous System Investigational
 Drugs (2000), 2(4), 461-466
 CODEN: COCDFA; ISSN: 1464-844X
 PY 2000

L4 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
 TI MKC-231 for treatment of Alzheimer's disease
 AU Takashina, Ken
 AB A review, with 2 refs., on the prehistory of development of the choline
 uptake enhancer MKC-231 and its pharmacol. properties.
 SO Rinsho to Yakubutsu Chiryo (2000), 19(1), 29-32
 CODEN: RYCHEI; ISSN: 0913-7505
 PY 2000

L4 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Central nervous system-mediated hyperglycemic effects of NIK-247, a
 cholinesterase inhibitor, and MKC-231, a choline uptake enhancer, in rats
 AU Uemura, Kazumasa; Yoshioka, Shuko; Surina-Baumgartner, Denise M.;
 Tamagawa, Tatsuo; Miura, Hisayuki; Ueda, Muneto; Tamaya, Norika; Iguchi,
 Akihisa; Hotta, Nigishi
 AB We investigated the effects of intracerebroventricular administration of

NIK-247 (9-amino-2,3,5,6,7,8-hexahydro-1H-cyclo-penta(b)-quinoline monohydrate hydrochloride; a cholinesterase inhibitor) or MKC-231 (2-(2-oxypyrrolidin-1-yl)-N-(2,3-dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl) acetoamide; a choline uptake enhancer) on plasma glucose level in comparison with that of neostigmine administration in rats. The extents of NIK-247- and MKC-231-induced hyperglycemia were considerably less than that by neostigmine, suggesting that the potencies of the drugs to produce the peripheral hyperglycemia may be pharmacol. negligible.

SO Japanese Journal of Pharmacology (1999), 79(1), 113-115

CODEN: JJPAAZ; ISSN: 0021-5198

PY 1999

L4 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN

TI Protective effect of MKC-231, a novel high affinity choline uptake enhancer, on glutamate cytotoxicity in cultured cortical neurons

AU Akaike, Akinori; Maeda, Takehiko; Kaneko, Satoshi; Tamura, Yutaka

AB The neuroprotective action of MKC-231, which enhances choline uptake and acetylcholine release in the central nervous system, was studied in vitro. Glutamate neurotoxicity was assessed with cortical cultures obtained from fetal rats. Exposure of cultures to MKC-231 for 12-24 h ameliorated the glutamate cytotoxicity. MKC-231 reduced the cytotoxicity induced by ionomycin, a calcium ionophore, but did not affect the cytotoxicity induced by S-nitrosocysteine, a nitric oxide (NO) donor. MKC-231 may protect against glutamate neurotoxicity by suppressing the NO formation triggered by Ca²⁺-influx.

SO Japanese Journal of Pharmacology (1998), 76(2), 219-222

CODEN: JJPAAZ; ISSN: 0021-5198


PY 1998

L4 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN

TI Acyltetrahydrofuroquinoline derivs. for prevention and treatment of mental disorders from impairment of brain cholinergic system

IN Saito, Kenichi; Betsusho, Tomoko; Chaki, Haruyuki; Egawa, Mitsuo

GI



AB 4-Acyltetrahydrofuro[2,3-b]quinoline derivs. (I; R1 = C2-C6 alkyl; R2 and R3 = H or C1-C4 alkyl; R4 = H or C1-C6 alkyl) and their pharmaceutical-acceptable salts are claimed for prevention and treatment of mental disorders from impairment of brain cholinergic system such as parkinsonism, Huntington's disease, Dawn syndrome, myasthenia gravis, glaucoma, and delayed exercise injury. 2-(2-Oxopyrrolidin-1-yl)-N-(2,3-dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl) acetoamide improved water-maze memory impairment in rats.

SO Jpn. Kokai Tokkyo Koho, 5 pp.

CODEN: JKXXAF

PY 1996

L4 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN

TI Effect of the novel high affinity choline uptake enhancer

2-(2-oxopyrrolidin-1-yl)-N-(2,3-dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)acetamide on deficits of water maze learning in rats

AU Bessho, Tomoko; Takashina, Ken; Tabata, Reiko; Ohshima, Chieko; Chaki, Haruyuki; Yamabe, Haruko; Egawa, Mitsuo; Tobe, Akihiro; Saito, Ken-Ichi

AB The pharmacol. properties of the title drug MKC-231 in comparison with an

acetylcholinesterase (AChE) inhibitor, tacrine were studied. MKC-231 (10-10-10-6 mol/l) significantly increased high affinity choline uptake (HACU) when it was incubated with the hippocampal synaptosomes of ethylcholine mustard aziridinium ion (AF64A) treated rats, but not of normal rats. MKC-231 did not affect the AChE activity, [3H]-quinuclidinyl benzilate binding, and [3H]-pirenzepine binding. Oral administration of MKC-231 (1-10 mg/kg) significantly improved the learning deficits in the Morris water maze of AF64A-treated rats, but it did not produce any significant side effects, like tremor, salivation or hypothermia, which were observed in rats treated with high doses of tacrine. Tacrine (0.1-3 mg/kg p.o.) failed to ameliorate the learning deficits in AF64A-treated rats. These results suggest that MKC-231 is a novel and quite unique compound, which improves the memory impairment induced by AF64A through the enhancement of HACU without any side effects at the EDs.

SO Arzneimittel-Forschung (1996), 46(4), 369-373

CODEN: ARZNAD; ISSN: 0004-4172


PY 1996

L4 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN

TI Design and synthesis of 4-(acylamino)pyridine derivatives: novel high affinity choline uptake enhancers. II.

AU Chaki, Haruyuki; Yamabe, Haruko; Sugano, Mamoru; Morita, Shuji; Bessho, Tomoko; Tabata, Reiko; Saito, Ken-Ichi; Egawa, Mitsuo; Tobe, Akihiro; Morinaka, Yasuhiro

GI



AB The synthesis of 4-(acylamino)pyridine derivs. and their high affinity choline uptake improvement activities are described. Acridine derivative I was selected as a lead compound. Modification of its ring structure and acyl moiety led to some active compds. Among them, furoquinoline derivative II (MKC-231) showed the highest activity. This compound is expected to be a unique medicine for Alzheimer's disease.

SO Bioorganic & Medicinal Chemistry Letters (1995), 5(14), 1495-500

CODEN: BMCLE8; ISSN: 0960-894X

PY 1995

L4 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN

TI MKC-231, a choline uptake enhancer, ameliorates working memory deficits and decreased hippocampal acetylcholine induced by ethylcholine aziridinium ion in mice

AU Murai, S.; Saito, H.; Abe, E.; Masuda, Y.; Odashima, J.; Itoh, T.

AB The effects of acute and chronic administration of MKC-231, a new choline uptake enhancer, and two other nootropic agents, linopiridine (Dup 996) and tetrahydroaminoacridine (THA) on working memory deficits and decreased hippocampal acetylcholine (ACh) content were studied in a delayed non-matching to sample task, using a T-maze, in ethylcholine aziridinium ion (AF64A)-treated mice. Treatment with AF64A (3.5 nmol, i.c.v.) produced memory deficits and decreased hippocampal ACh content. In acute behavioral expts., MKC-231 and THA had no significant effect on AF64A-induced memory deficits at any doses tested (0.3, 1.0 and 3.0 mg/kg), whereas Dup 996, at a dose of 1.0 mg/kg, significantly improved

memory deficits. In chronic expts., MKC-231 improved memory deficit at all doses tested (0.3, 1.0, or 3.0 mg/kg p.o., once daily for 11 days) and Dup 996 did so only at a dose of 3.0 mg/kg, whereas THA did not improve memory deficit at any doses tested. In acute neurochem. expts., MKC-231 and THA did not reverse the AF64A-induced hippocampal ACh depletion. Dup 996, however, further decreased hippocampal ACh content compared to that in the AF64A-treated group. In chronic expts., MKC-231 significantly reversed hippocampal ACh depletion at doses of 0.3 and 1.0 mg/kg, whereas neither Dup 996 nor THA reversed hippocampal ACh depletion at any doses tested. These results indicate that MKC-231 improved the AF64A-induced working memory deficit and hippocampal ACh depletion, probably by recovering reduced high-affinity choline uptake and ACh release.

SO Journal of Neural Transmission: General Section (1994), 98(1), 1-13
CODEN: JNGSE8; ISSN: 0300-9564



PY 1994

L4 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN

TI Preparation of 4-acylaminopyridine derivatives for treatment of Alzheimer's disease

IN Ninomiya, Kunihiro; Saito, Kenichi; Sugano, Mamoru; Tobe, Akihiro; Morinaka, Yasuhiro; Bessho, Tomoko; Harada, Haruko

GI



AB The title compds. I [R1 = C2-C6 alkyl, (CH₂)_nNR₂R₃, CHR₄CO₂R₅, NR₂R₃ = 2-oxo-1-pyrrolidinyl, R₇; R₂, R₃ = independently H, C1-C6 alkyl, C3-C6 cycloalkyl, R₄, R₅, R₆ = independently H, C1-C6 alkyl; n = 0-3; ring A = fused cyclopentyl, cyclohexyl, substituted benzo, substituted thieno, substituted furo, pyrido; ring B = fused cycloalkyl, bicycloalkyl] or a pharmaceutically acceptable acid-added salt thereof were prepared as agents for treatment of Alzheimer's disease. Thus, cyclization of I (R1 = CH₂-L-Val-OMe, ring A = benzo, ring B = cyclohexano) (preparation given) gave I [R1 = CH₂R₇; R₆ = (S)-CHMe₂] which showed 20% improvement at 10⁻⁸ M in a sodium-dependent high-affinity choline uptake ability test.

SO Eur. Pat. Appl., 100 pp.

CODEN: EPXXDW

PY 1991

1991

1996

1991

1998

1991

2000

1991

1996

1991

2002

1996

1996

1999

1995

1996

1999

=> file reg
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
42.91	111.27

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-10.92	-10.92

CA SUBSCRIBER PRICE

FILE 'REGISTRY' ENTERED AT 15:26:44 ON 29 JAN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 28 JAN 2007 HIGHEST RN 918629-37-5
DICTIONARY FILE UPDATES: 28 JAN 2007 HIGHEST RN 918629-37-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> E "MKC-231"/CN 25

E1	1	MKC SILICATE MSH 1/CN
E2	1	MKC SILICATE MSH 6/CN
E3	0 -->	MKC-231/CN
E4	1	MKC-S/CN
E5	1	MKC7 PROTEASE/CN
E6	1	MKD/CN
E7	1	MKE 301/CN
E8	1	MKF 111/CN
E9	1	MKF 18/CN
E10	1	MKF 186/CN
E11	1	MKF 18U/CN
E12	1	MKF 199/CN
E13	1	MKF 211/CN
E14	1	MKF 29/CN
E15	1	MKF 300/CN
E16	1	MKF 674/CN
E17	1	MKF 726/CN
E18	1	MKF 728/CN
E19	1	MKF 736/CN
E20	1	MKF 740/CN
E21	1	MKF 790/CN
E22	1	MKFK/CN
E23	1	MKG/CN
E24	1	MKG 11/CN
E25	1	MKH/CN

=> E "MKC 231"/CN 25

E1	1	MKC/CN
E2	1	MKC 1PH/CN

E3 1 --> MKC 231/CN
 E4 1 MKC 242/CN
 E5 1 MKC 431/CN
 E6 1 MKC 442/CN
 E7 1 MKC 454/CN
 E8 1 MKC 733/CN
 E9 1 MKC 963/CN
 E10 1 MKC SILICATE 51/CN
 E11 1 MKC SILICATE 56/CN
 E12 1 MKC SILICATE 56 ETHYL ESTER/CN
 E13 1 MKC SILICATE BTS/CN
 E14 1 MKC SILICATE MS 1200/CN
 E15 1 MKC SILICATE MS 41/CN
 E16 1 MKC SILICATE MS 51/CN
 E17 1 MKC SILICATE MS 51SG1/CN
 E18 1 MKC SILICATE MS 56/CN
 E19 1 MKC SILICATE MS 56S/CN
 E20 1 MKC SILICATE MS 56SB5/CN
 E21 1 MKC SILICATE MS 56SB5, POLYMER WITH
 A-HYDRO- Ω -HYDROXPOLY(OXY-1,2-ETHANEDIYL)/CN
 E22 1 MKC SILICATE MS 56SB5, POLYMER WITH 2-HYDROXYETHYL
 2-METHYL-2-PROPENOATE, METHYL 2-METHYL-2-PROPENOATE AND 2-PROPENOIC ACID/CN
 E23 1 MKC SILICATE MS 57/CN
 E24 1 MKC SILICATE MS 58B15/CN
 E25 1 MKC SILICATE MS 58B30/CN

=> S E3

L5 1 "MKC 231"/CN

=> DIS L5 1 IDE

L5 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN

RN 135463-81-9 REGISTRY

ED Entered STN: 09 Aug 1991

CN 1-Pyrrolidineacetamide, 2-oxo-N-(5,6,7,8-tetrahydro-2,3-dimethylfuro[2,3-b]quinolin-4-yl)-(9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Furo[2,3-b]quinoline, 1-pyrrolidineacetamide deriv.

OTHER NAMES:


CN Coluracetam

CN MKC 231

MF C19 H23 N3 O3

SR CA

LC STN Files: ADISINSIGHT, BIOSIS, BIOTECHNO, CA, CAPLUS, CIN, EMBASE, IMSDRUGNEWS, IMSRESEARCH, MEDLINE, PHAR, PROMT, PROUSDDR, SCISEARCH, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

14 REFERENCES IN FILE CA (1907 TO DATE)
14 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
7.80	119.07

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-10.92

CA SUBSCRIBER PRICE

FILE 'CAPLUS' ENTERED AT 15:28:00 ON 29 JAN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 29 Jan 2007 VOL 146 ISS 6
FILE LAST UPDATED: 28 Jan 2007 (20070128/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> d his

(FILE 'HOME' ENTERED AT 15:20:55 ON 29 JAN 2007)

FILE 'REGISTRY' ENTERED AT 15:21:09 ON 29 JAN 2007

L1 STRUCTURE UPLOADED
L2 0 S L1 FAM SAM

L3 1 S L1 FAM FULL

FILE 'CAPLUS' ENTERED AT 15:22:17 ON 29 JAN 2007

L4 14 S L3

FILE 'REGISTRY' ENTERED AT 15:26:44 ON 29 JAN 2007

E "MKC-231"/CN 25

E "MKC 231"/CN 25

L5 1 S E3

FILE 'CAPLUS' ENTERED AT 15:28:00 ON 29 JAN 2007

=> s l4 or 135463-81-9 or mkc-231 or mkc(a)231

REGISTRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...

Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

L7 14 L6

399 MKC

2 MKCS

400 MKC

(MKC OR MKCS)

20307 231

9 MKC-231

(MKC(W)231)

399 MKC

2 MKCS

400 MKC

(MKC OR MKCS)

20307 231

9 MKC(A)231

L8 15 L4 OR L7 OR MKC-231 OR MKC(A)231

=> d ti au so py 1-15

L8 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN

TI "Lead Hopping". Validation of Topomer Similarity as a Superior Predictor of Similar Biological Activities

AU Cramer, Richard D.; Jilek, Robert J.; Guessregen, Stefan; Clark, Stephanie J.; Wendt, Bernd; Clark, Robert D.

SO Journal of Medicinal Chemistry (2004), 47(27), 6777-6791

CODEN: JMCMAR; ISSN: 0022-2623

PY 2004

L8 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN

TI Fused pyridine derivative used as therapeutic agent for schizophrenia

IN Bessho, Tomoko; Takashina, Ken

SO PCT Int. Appl., 31 pp.

CODEN: PIXXD2

PY 2004

2004

2005

2006

2006

L8 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Preventives/remedies for cholinergic neuropathy
 IN Takashina, Ken; Bessho, Tomoko
 SO PCT Int. Appl., 57 pp.
 CODEN: PIXXD2
 PY 2003
 2003
 2004
 2004

L8 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Polymorph forms of n-(2,3-dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)-2-(2-oxopyrrolidin-1-yl)acetamide
 IN Yamabe, Haruko; Ishige, Takanori
 SO PCT Int. Appl., 35 pp.
 CODEN: PIXXD2
 PY 2002
 2002
 2004
 2004
 2004
 2004
 2005

L8 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
 TI 4-Acylaminotetrahydrofuro[2,3-b]quinoline derivatives for prevention and treatment of ischemic retinopathy and retinal and optic nerve injury
 IN Togawa, Shunji; Mano, Tomiya; Yano, Shinji
 SO Jpn. Kokai Tokkyo Koho, 7 pp.
 CODEN: JKXXAF
 PY 2001

L8 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
 TI MKC-231, Mitsubishi-Tokyo Pharmaceutical Inc
 AU Chen, Yun
 SO Current Opinion in Central & Peripheral Nervous System Investigational Drugs (2000), 2(4), 461-466
 CODEN: COCDFA; ISSN: 1464-844X
 PY 2000

L8 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
 TI MKC-231 for treatment of Alzheimer's disease
 AU Takashina, Ken
 SO Rinsho to Yakubutsu Chiryo (2000), 19(1), 29-32
 CODEN: RYCHEI; ISSN: 0913-7505
 PY 2000

L8 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Central nervous system-mediated hyperglycemic effects of NIK-247, a cholinesterase inhibitor, and MKC-231, a choline uptake enhancer, in rats
 AU Uemura, Kazumasa; Yoshioka, Shuko; Surina-Baumgartner, Denise M.; Tamagawa, Tatsuo; Miura, Hisayuki; Ueda, Muneto; Tamaya, Norika; Iguchi, Akihisa; Hotta, Nigishi
 SO Japanese Journal of Pharmacology (1999), 79(1), 113-115
 CODEN: JJPAAZ; ISSN: 0021-5198
 PY 1999

L8 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Protective effect of MKC-231, a novel high affinity choline uptake enhancer, on glutamate cytotoxicity in cultured cortical neurons
 AU Akaike, Akinori; Maeda, Takehiko; Kaneko, Satoshi; Tamura, Yutaka
 SO Japanese Journal of Pharmacology (1998), 76(2), 219-222

CODEN: JJPAAZ; ISSN: 0021-5198

PY 1998

L8 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
TI Acyltetrahydrofuroquinoline derivs. for prevention and treatment of mental disorders from impairment of brain cholinergic system
IN Saito, Kenichi; Betsusho, Tomoko; Chaki, Haruyuki; Egawa, Mitsuo
SO Jpn. Kokai Tokkyo Koho, 5 pp.

CODEN: JKXXAF

PY 1996

L8 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
TI Effect of the novel high affinity choline uptake enhancer
2-(2-oxopyrrolidin-1-yl)-N-(2,3-dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)acetamide on deficits of water maze learning in rats
AU Bessho, Tomoko; Takashina, Ken; Tabata, Reiko; Ohshima, Chieko; Chaki, Haruyuki; Yamabe, Haruko; Egawa, Mitsuo; Tobe, Akihiro; Saito, Ken-Ichi
SO Arzneimittelforschung (1996), 46(4), 369-373

CODEN: ARZNAD; ISSN: 0004-4172

PY 1996

L8 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
TI Syntheses and structure-activity relationship of 4-acylaminopyridine derivatives: Novel high affinity choline uptake enhancers.
AU Chaki, Haruyuki; Yamabe, Haruko; Sugano, Mamoru; Morita, Shuji; Bessho, Tomoko; Tabata, Reiko; Saito, Ken-Ichi; Egawa, Mitsuo; Tobe, Akihiro; Morinaka, Yasuhiro
SO Book of Abstracts, 210th ACS National Meeting, Chicago, IL, August 20-24 (1995), Issue Pt. 2, MEDI-146 Publisher: American Chemical Society, Washington, D. C.

CODEN: 61XGAC

PY 1995

L8 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
TI Design and synthesis of 4-(acylamino)pyridine derivatives: novel high affinity choline uptake enhancers. II.
AU Chaki, Haruyuki; Yamabe, Haruko; Sugano, Mamoru; Morita, Shuji; Bessho, Tomoko; Tabata, Reiko; Saito, Ken-Ichi; Egawa, Mitsuo; Tobe, Akihiro; Morinaka, Yasuhiro
SO Bioorganic & Medicinal Chemistry Letters (1995), 5(14), 1495-500

CODEN: BMCLE8; ISSN: 0960-894X

PY 1995

L8 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
TI MKC-231, a choline uptake enhancer, ameliorates working memory deficits and decreased hippocampal acetylcholine induced by ethylcholine aziridinium ion in mice

AU Murai, S.; Saito, H.; Abe, E.; Masuda, Y.; Odashima, J.; Itoh, T.

SO Journal of Neural Transmission: General Section (1994), 98(1), 1-13

CODEN: JNGSE8; ISSN: 0300-9564

PY 1994

L8 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of 4-acylaminopyridine derivatives for treatment of Alzheimer's disease
IN Ninomiya, Kunihiro; Saito, Kenichi; Sugano, Mamoru; Tobe, Akihiro; Morinaka, Yasuhiro; Bessho, Tomoko; Harada, Haruko
SO Eur. Pat. Appl., 100 pp.

CODEN: EPXXDW

PY 1991

1991

1996

1991

1998

1991
2000
1991
1996
1991
2002
1996
1996
1999
1995
1996
1999

=> s 135463-81-9

REGISTRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...

Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

L10 14 L9

=> s schizophreni?

L11 17183 SCHIZOPHRENI?

=> d his

(FILE 'HOME' ENTERED AT 15:20:55 ON 29 JAN 2007)

FILE 'REGISTRY' ENTERED AT 15:21:09 ON 29 JAN 2007

L1 STRUCTURE UPLOADED

L2 0 S L1 FAM SAM

L3 1 S L1 FAM FULL

FILE 'CAPLUS' ENTERED AT 15:22:17 ON 29 JAN 2007

L4 14 S L3

FILE 'REGISTRY' ENTERED AT 15:26:44 ON 29 JAN 2007

E "MKC-231"/CN 25

E "MKC 231"/CN 25

L5 1 S E3

FILE 'CAPLUS' ENTERED AT 15:28:00 ON 29 JAN 2007

S L4 OR 135463-81-9/REG# OR MKC-231 OR MKC(A)231

FILE 'REGISTRY' ENTERED AT 15:29:09 ON 29 JAN 2007

L6 1 S 135463-81-9/RN

FILE 'CAPLUS' ENTERED AT 15:29:10 ON 29 JAN 2007

L7 14 S L6

L8 15 S L4 OR L7 OR MKC-231 OR MKC(A)231

S 135463-81-9/REG#

FILE 'REGISTRY' ENTERED AT 15:30:28 ON 29 JAN 2007

L9 1 S 135463-81-9/RN

FILE 'CAPLUS' ENTERED AT 15:30:29 ON 29 JAN 2007

L10 14 S L9

L11 17183 S SCHIZOPHRENI?

=> s 18 and l11

L12 1 L8 AND L11

=>